coronary artery disease
Conditions
Interventions
control group:Rivaroxaban + DAPT
control group:Basic treatment
Sponsors
China-Japan Union Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients were eligible for this trial if they met the criteria for anterior STEMI after primary PCI from October 2019 and December 2022; 2. Willing to participate in this trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) intracranial, gastrointestinal, urogenital bleeding within 3 months; 2) drug allergy in this study; 3) severe liver and kidney diseases, chronic renal failure, serum creatinine >3.0 mg/dl; Transaminase exceeded the reference value by more than 3 times; 4) currently taking Rivaroxaban or requiring long-term anticoagulation therapy; 5) pregnancy and malignant tumors; 6)confirmed or suspected hematological diseases (except mild or moderate anemia); 7) thrombocytopenia, platelets <100,000/ml; 8) a high risk of bleeding was assessed by the CRUSADE score; 9) older than 75 years or less than 18 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the formation of left ventricular thrombus; | — |
Countries
China
Contacts
Public ContactWenqi Zhang
China-Japan Union Hospital of Jilin University
Outcome results
None listed